DIRECT

Direct Diabetes

The overarching aims of the European consortium are to identify biomarkers that address current bottlenecks in diabetes drug development and to develop a stratified medicines approach to the treatment of type 2 diabetes with either existing or novel therapies. The identification and validation of important biomarkers for glycaemic deterioration and treatment response may be used to predict and monitor the effect of therapeutic interventions in subtypes of diabetes with different pathophysiology.

50.000.000 euro

Data collection and scientific involvement

Click to read more (external website)